Focusing on the RLR pathway, a potential pathway in the context of cancer in general and DLBCL in particular, we find that MAVS, the central RLR adaptor molecule, while not mutated, is robustly edited (Figure 2C), with editing correlated with increased gene and protein expression levels and increased downstream signaling (Figure 3). The gene discussed is DHX58; the disease is diffuse large B-cell lymphoma.